Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Canine influenza virus H3N8 is an RNA virus of the Orthomyxoviridae family, subtype Influenza A virus H3N8, responsible for causing highly contagious respiratory disease in dogs. This strain originated from equine H3N8 influenza, adapted to infect dogs around 2004 in the USA, and is commonly known as the “original” canine influenza virus strain. It is characterized by its two major surface proteins, hemagglutinin (H) and neuraminidase (N), specifically of the H3 and N8 subtypes. The virus rapidly spreads between dogs, especially in environments where dogs congregate, but current evidence suggests minimal risk of cross-species (dog-to-human or dog-to-horse) infection[1][2][6][7][9][10].
Inhibition of viral neuraminidase (for antiviral drugs like oseltamivir; targets the NA protein, not the virus as a whole)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Canine influenza virus H3N8 (CIV H3N8).